Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • The US Patent and Trademark Office has granted Nextleaf a patent pertaining to the modification of THC into a more potent prodrug version of THC-O-acetate
  • Nextleaf believes that the prodrug may hold potential as a therapeutic product
  • Nextleaf is exploring opportunities to commercialize this patent
  • Nextleaf is the first company in the world to be issued patents for the production of THC-O-Acetate
  • Nextleaf Solutions is an innovative cannabis processor that owns one of the largest portfolios of U.S. patents for the extraction, distillation, and delivery of cannabinoids
  • Nextleaf Solutions is unchanged, trading at C$0.26 per share at 10:30 am ET

Nextleaf has been awarded a patent for the modification of THC into a more potent prodrug version of THC-O-acetate.

Nextleaf believes the THC-derived prodrug produced under its patented process may hold potential as a therapeutic product for the treatment of chronic pain, PTSD, and alcohol use disorder.

“The U.S. continues to be the focal point of our global IP strategy,” said Nextleaf CEO Paul Pedersen.

“Between operating our cannabinoid innovation lab under strict federal regulations in Canada where cannabis is federally legal and owning one of the largest U.S. patent portfolios of any cannabis company, Nextleaf has the type of robust intellectual property portfolio and scalable commercial platform that large pharmaceuticals and big tobacco companies have already targeted with M&A in 2021.”   

“This U.S. patent covers our method of THC acetylation and follows our previous patent for synthesizing THC-O-acetate, with improvements to reaction efficiencies,” said Nextleaf Solutions R&D Lead, Dr. David Novitski.

“Our latest patented method reduces processing time and costs, which are critical when scaling up any drug delivery technology, and THC-O-acetate is no different.” 

“To the best of our knowledge, Nextleaf is the first company in the world, publicly traded or private, to be issued patents for the production of THC-O-Acetate, a specialty molecule not legally available anywhere in the world,” said Pedersen. 

Nextleaf Solutions is an innovative cannabis processor that owns one of the largest portfolios of U.S. patents for the extraction, distillation, and delivery of cannabinoids.

Nextleaf Solutions is unchanged, trading at C$0.26 per share at 10:30 am ET.

More From The Market Herald

" Nutritional High’s (CSE:EAT) California businesses aided by new ordinance vote

Nutritional High’s (EAT) OutCo acquisition will benefit from a recent vote by the San Diego County Board of Supervisors.

" VIVO Cannabis™ (TSX:VIVO) completes first shipment to Beacon Medical Germany GmbH

VIVO Cannabis’s (VIVO) subsidiary ABcann Medicinals has completed its first shipment of EU-GMP certified Canadian dried flower medical cannabis into Europe.
BioHarvest Sciences - David Tsur

" BioHarvest Sciences (CSE:BHSC) appoints David Tsur to its board of directors

BioHarvest Sciences (BHSC) has announced that, effective immediately, David Tsur will serve as a non-executive director of the company.

" Maple Leaf Green World (CSE:MGW) unveils new CBG wellness brand

Maple Leaf Green World (MGW) is launching a new health and wellness brand, RèNao Wellness.